Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA issues H1N1 warning letters

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Cashburners, the website manager and host site for Flu Defence dietary supplement - sold on fludefence.org, fludefence.net and swinefludefence.org - to stop marketing the supplement, because it is unapproved by FDA to diagnose, mitigate, prevent, treat or cure H1N1. In warning letters sent June 2 to the domain protector and website marketer located in New Zealand, the Netherlands and Westchester, Calif., the agency takes issue with claims including "[E]xhibits strong antiviral action against influenza A & 8, birdflu ... swine flu." FDA teamed with the Federal Trade Commission and foreign governments to root out improper claims regarding products that treat or prevent H1N1 flu (1"The Tan Sheet" Oct. 19, 2009). FDA also warned Nature's Gift in a letter posted June 11 to discontinue claims on its blog that Flu Foil Synergy, Flu Foil Synergy with Inhaler, Ravensara and Ravintsara could diagnose, mitigate, prevent, treat or cure H1N1 because the products are unapproved

You may also be interested in...



FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel